Development of graft-versus-host disease (GvHD) is a rare complication after transfusions or solid organ transplantation. Patients typically present with a skin rash, diarrhea, liver failure, and bone marrow aplasia. A diagnosis of transfusion/transplantation associated-GvHD is made based on the clinical and histologic evidence, yet it is often delayed due to the nonspecific symptoms attributed to the patient's underlying illness. Several therapeutic approaches are being used including both increasing and withdrawing immunosuppression, and the use of cellular therapies. Unfortunately, the success rate of these approaches is low and the mortality of this complication is very high. New approaches are needed. We report on three cases of GvHD developing after solid organ transplantation treated with ruxolitinib.

Original languageEnglish
Pages (from-to)589-592
Number of pages4
JournalAmerican Journal of Transplantation
Issue number2
StatePublished - Feb 1 2020


  • clinical research/practice
  • graft-versus-host disease (GVHD)
  • hematology/oncology
  • immunosuppressant - other
  • immunosuppression/immune modulation
  • organ transplantation in general


Dive into the research topics of 'The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation'. Together they form a unique fingerprint.

Cite this